Latest period
$8.07B
YoY change
+19.2%
5Y CAGR
+31.6%
Peak year (2009)
$8.78B
Latest annual
$8.67B
Free Cash Flow history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $8.67B
Free Cash Flow growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +19.2%
Free Cash Flow history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $8.67B | +19.2% | +$1.40B | ||
| 2024 | $7.28B | +10.8% | +$708.00M | ||
| 2023 | $6.57B | -9.3% | −$670.00M | ||
| 2022 | $7.24B | +92.3% | +$3.47B | ||
| 2021 | $3.76B | +71.6% | +$1.57B | ||
| 2020 | $2.19B | +330.8% | +$1.68B | ||
| 2019 | $509.00M | -59.2% | −$738.00M | ||
| 2018 | $1.25B | -36.3% | −$711.00M | ||
| 2017 | $1.96B | +6.9% | +$127.00M | ||
| 2016 | $1.83B | +241.6% | +$1.29B | ||
| 2015 | $536.00M | -87.6% | −$3.77B | ||
| 2014 | $4.31B | -19.4% | −$1.04B | ||
| 2013 | $5.34B | +129.4% | +$3.01B | ||
| 2012 | $2.33B | -64.3% | −$4.20B | ||
| 2011 | $6.52B | -21.0% | −$1.74B | ||
| 2010 | $8.26B | -5.9% | −$522.00M | ||
| 2009 | $8.78B | +86.7% | +$4.08B | ||
| 2008 | $4.70B | -19.3% | −$1.13B | ||
| 2007 | $5.83B | -8.2% | −$523.00M | ||
| 2006 | $6.35B | +10.2% | +$590.00M | ||
| 2005 | $5.76B | +26.9% | +$1.22B | ||
| 2004 | $4.54B | +112.8% | +$2.41B | ||
| 2003 | $2.13B | -38.9% | −$1.36B | ||
| 2002 | $3.49B | +687.0% | +$3.05B | ||
| 2001 | $443.83M | -49.3% | −$431.43M | ||
| 2000 | $875.25M | -147.5% | +$2.72B | ||
| 1999 | −$1.84B | -5387.5% | −$1.88B | ||
| 1998 | $34.86M | -521.7% | +$43.12M | ||
| 1997 | −$8.27M | -105.5% | −$157.25M | ||
| 1996 | $148.99M | -3.6% | −$5.53M | ||
| 1995 | $154.52M | +16.3% | +$21.63M | ||
| 1994 | $132.89M | -45.2% | −$109.70M | ||
| 1993 | $242.59M | -221.2% | +$442.79M | ||
| 1992 | −$200.20M | -267.2% | −$319.96M | ||
| 1991 | $119.76M | -55.0% | −$146.44M | ||
| 1990 | $266.19M | — | — |
- 2025$8.67B+19.2%
- 2024$7.28B+10.8%
- 2023$6.57B-9.3%
- 2022$7.24B+92.3%
- 2021$3.76B+71.6%
- 2020$2.19B+330.8%
- 2019$509.00M-59.2%
- 2018$1.25B-36.3%
- 2017$1.96B+6.9%
- 2016$1.83B+241.6%
- 2015$536.00M-87.6%
- 2014$4.31B-19.4%
- 2013$5.34B+129.4%
- 2012$2.33B-64.3%
- 2011$6.52B-21.0%
- 2010$8.26B-5.9%
- 2009$8.78B+86.7%
- 2008$4.70B-19.3%
- 2007$5.83B-8.2%
- 2006$6.35B+10.2%
- 2005$5.76B+26.9%
- 2004$4.54B+112.8%
- 2003$2.13B-38.9%
- 2002$3.49B+687.0%
- 2001$443.83M-49.3%
- 2000$875.25M-147.5%
- 1999−$1.84B-5387.5%
- 1998$34.86M-521.7%
- 1997−$8.27M-105.5%
- 1996$148.99M-3.6%
- 1995$154.52M+16.3%
- 1994$132.89M-45.2%
- 1993$242.59M-221.2%
- 1992−$200.20M-267.2%
- 1991$119.76M-55.0%
- 1990$266.19M—
Free Cash Flow values are taken from AstraZeneca's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at AstraZeneca (AZN)
Free Cash Flow for AstraZeneca (AZN): headline value $8.07B · YoY +19.2%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AstraZeneca (AZN) most recent annual free cash flow stands at $8.67B (2025) – grew 19.2% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca free cash flow compounded at +31.6% per year, sustaining 2 straight years of year-over-year growth.
Between 2009 and 2025, AstraZeneca free cash flow edged down 1.3%, falling from $8.78B to $8.67B.
The record annual free cash flow stands at $8.78B, reached in 2009; the historical low of −$1.84B was recorded in 1999.
AstraZeneca Free Cash Flow by Year
AstraZeneca Free Cash Flow 2025: $8.67B
In 2025, AstraZeneca reported free cash flow of $8.67B, grew 19.2% from 2024.
AstraZeneca Free Cash Flow 2024: $7.28B
AstraZeneca free cash flow in 2024 was $7.28B, grew 10.8% from 2023.
AstraZeneca Free Cash Flow 2023: $6.57B
2023's free cash flow for AstraZeneca came in at $6.57B, declined 9.3% below 2022.
AstraZeneca Free Cash Flow 2022: $7.24B
AstraZeneca posted free cash flow of $7.24B in 2022, surged 92.3% from 2021.
AstraZeneca Free Cash Flow 2021: $3.76B
AstraZeneca free cash flow in 2021 was $3.76B.
See more financial history for AstraZeneca (AZN).
Sector peers by Free Cash Flow
Healthcare peers of AstraZeneca (AZN), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $8.97B | |
| $8.10B | |
| $6.29B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $8.97B
- $8.10B
- $4.52B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation